DUBLIN, Jan. 29, 2015 /PRNewswire/ --Research and
Markets
(http://www.researchandmarkets.com/research/m5wdw9/small_molecule)
has announced the addition of the "Small Molecule Cancer Drug
Clinical Pipeline Insight 2015" report to their offering.
Oncologists are continuously looking for better therapeutic
options to effectively cure and prevent different types of
malignancies. Conventionally, surgery and radiation were widely
used for cancer treatment but they have modest benefits. Presently,
global market consists of several options for cancer treatment
which belongs to various classes of molecules. Their utilization in
therapeutic regime depends on the patient's medical condition,
pharmacological and financial benefits offered by them during
treatment. Out of these classes of therapeutic molecules, small
molecules have been found to have substantial impact on cancer
treatment due to which they are widely accepted by oncologists and
patients.
Small molecules are widely used for cancer treatment because they
can easily infiltrate into the tumorous cells and prevent its
proliferation. Chemotherapeutic drugs are also small molecules,
generally used in cancer treatment for several decades. They are
still used as first line cancer therapeutics and they have highly
developed cancer market. Chemotherapeutics have helped in
decreasing the mortality rates but their severe side effects cause
high morbidity rates. This fact made the researchers to search for
other small molecules which can provide better pharmacological
effects with minimized side effects in cancer patients. As a
result, after several decades of research newer small molecules
belonging to different classes have been formulated for cancer
treatment.
High versatility is another benefit offered by small molecule due
to which they can be used for the treating different types of
cancers. Research in this field is progressing and several
molecules are under investigation for their pharmacological
efficacy. Conventional therapies in cancer of sensitive tissue may
have life threatening effects instead of therapeutic benefit. For
instance, a newly discovered molecule called TIC10 has been found
as a potential treatment against brain tumour. It is under
development at laboratory phase and someday it may enter in
clinical trials in coming years. Many other small molecules are
under development for the treatment of Non-Small Cell Lung Cancer
(NSCLC), Colon cancer, Breast and other cancers.
Development of small molecule cancer drug generally involves target
identification and pharmacological efficacy provided during
clinical trials. Different types of cancer have different
physiological characteristics due to which effective treatment
requires the small molecule showing preferential selectiveness
towards a particular cell group. Technological limitations are one
of the biggest hindrances in the speedy development of small
molecules for cancer treatment but this is expected to be overcome
with time due to increased investments in research and development
segment. New small cancer drugs based on novel technology are
expected to enter in global market in coming years.
Small Molecule Cancer Drug Clinical Pipeline Insight Report
Findings:
- Role of Small Molecule Drug in Cancer Treatment
- Mechanism of Small Molecule Cancer Drug
- Small Molecule Cancer Drugs Market Dynamics
- Small Molecule Cancer Drug Clinical Pipeline By Company,
Indication & Phase
- Small Molecule Cancer Drug Clinical Pipeline: 1108 Drugs
- Marketed Small Molecule Cancer Drugs: 128
- Majority of Drugs are in Preclinical Phase: 437 Drugs
Key Topics Covered:
1. Introduction to Small Molecule Cancer Drug
2. Role of Small Molecule Drug in Cancer Treatment
3. Mechanism of Small Molecule Cancer Drug
4. Small Molecule Cancer Drugs Market Overview
5. Small Molecule Cancer Drugs Market Dynamics
6. Small Molecule Cancer Drug Market Future Prospects
7. Small Molecule Cancer Drug Clinical Pipeline By Company,
Indication & Phase
8. Marketed Small Molecule Cancer Drugs Clinical Insight
9. Competitive Landscape
Companies Mentioned:
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Cadila Pharmaceutical
- Eli Lily
- GalaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
- Sun Pharmaceuticals
For more information visit
http://www.researchandmarkets.com/research/m5wdw9/small_molecule
Media Contact: Laura Wood
, +353-1-481-1716, press@researchandmarkets.net